uniQure N.V. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
uniQure N.V. (QURE) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-02
- uniQure N.V. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.30%.
- uniQure N.V. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.10%.
- uniQure N.V. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -0.30% 10-K · filed 2026-03-02 |
| 2024-12-31 | -0.10% 10-K · filed 2026-03-02 |
| 2023-12-31 | 0.00% 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |